CA2919996A1

CA2919996A1 - Methods for the treatment of solid tumors

Methods for the treatment of solid tumors Download PDF

Info

Publication number: CA2919996A1
Authority: CA; Canada
Prior art keywords: substituted; cancer; unsubstituted; carcinoma; combination
Prior art date: 2013-08-02
Legal status : Abandoned

Application number

CA2919996A

Other languages

English (en)

French (fr)

Inventor

Sriram Balasubramanian

Current Assignee

Pharmacyclics LLC

Original Assignee

Pharmacyclics LLC

Priority date

2013-08-02

Filing date

2014-08-01

Publication date

2015-02-05

2014-08-01 Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC

2015-02-05 Publication of CA2919996A1 publication Critical patent/CA2919996A1/en

Status Abandoned legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 216
238000011282 treatment Methods 0.000 title claims abstract description 85
238000000034 method Methods 0.000 title claims description 55
239000003112 inhibitor Substances 0.000 claims abstract description 151
239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 123
XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 247
239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 241
229960001507 ibrutinib Drugs 0.000 claims description 241
MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical group O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 203
229950008805 abexinostat Drugs 0.000 claims description 195
102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims description 157
101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims description 157
150000001875 compounds Chemical class 0.000 claims description 156
125000000217 alkyl group Chemical group 0.000 claims description 135
201000009030 Carcinoma Diseases 0.000 claims description 124
229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 122
229940124291 BTK inhibitor Drugs 0.000 claims description 106
239000000203 mixture Substances 0.000 claims description 95
125000000753 cycloalkyl group Chemical group 0.000 claims description 77
239000003814 drug Substances 0.000 claims description 77
-1 AG-F-54930) Chemical compound 0.000 claims description 73
125000001072 heteroaryl group Chemical group 0.000 claims description 64
125000003118 aryl group Chemical group 0.000 claims description 61
230000002427 irreversible effect Effects 0.000 claims description 52
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 49
101150015280 Cel gene Proteins 0.000 claims description 48
206010005003 Bladder cancer Diseases 0.000 claims description 47
201000005202 lung cancer Diseases 0.000 claims description 47
208000020816 lung neoplasm Diseases 0.000 claims description 47
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 46
208000009956 adenocarcinoma Diseases 0.000 claims description 46
201000005112 urinary bladder cancer Diseases 0.000 claims description 46
125000000623 heterocyclic group Chemical group 0.000 claims description 42
208000006990 cholangiocarcinoma Diseases 0.000 claims description 39
238000011260 co-administration Methods 0.000 claims description 38
206010004593 Bile duct cancer Diseases 0.000 claims description 37
206010033128 Ovarian cancer Diseases 0.000 claims description 37
206010039491 Sarcoma Diseases 0.000 claims description 37
RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims description 36
208000026310 Breast neoplasm Diseases 0.000 claims description 35
206010006187 Breast cancer Diseases 0.000 claims description 34
206010060862 Prostate cancer Diseases 0.000 claims description 33
125000003342 alkenyl group Chemical group 0.000 claims description 33
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 31
208000008443 pancreatic carcinoma Diseases 0.000 claims description 31
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 30
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 30
201000002528 pancreatic cancer Diseases 0.000 claims description 30
206010009944 Colon cancer Diseases 0.000 claims description 28
208000026900 bile duct neoplasm Diseases 0.000 claims description 28
125000004404 heteroalkyl group Chemical group 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 28
239000001257 hydrogen Substances 0.000 claims description 28
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 28
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 28
239000002552 dosage form Substances 0.000 claims description 27
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
206010061535 Ovarian neoplasm Diseases 0.000 claims description 26
125000000304 alkynyl group Chemical group 0.000 claims description 25
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 25
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 24
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 21
229910052799 carbon Inorganic materials 0.000 claims description 20
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 18
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 17
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 17
208000014081 polyp of colon Diseases 0.000 claims description 17
JIFCFQDXHMUPGP-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2N=C(NC=3C=CC(=CC=3)C(=O)N3CCOCC3)C(=O)N(C)C=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 JIFCFQDXHMUPGP-UHFFFAOYSA-N 0.000 claims description 16
125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 16
BSSBAJKNZOHHCA-UHFFFAOYSA-N 7-benzyl-1-(3-piperidin-1-ylpropyl)-2-(4-pyridin-4-ylphenyl)-5h-imidazo[4,5-g]quinoxalin-6-one Chemical compound C1CCCCN1CCCN1C=2C=C3N=C(CC=4C=CC=CC=4)C(=O)NC3=CC=2N=C1C(C=C1)=CC=C1C1=CC=NC=C1 BSSBAJKNZOHHCA-UHFFFAOYSA-N 0.000 claims description 16
125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 16
201000009546 lung large cell carcinoma Diseases 0.000 claims description 16
208000000649 small cell carcinoma Diseases 0.000 claims description 16
SMOPKEHQPPXRSH-UHFFFAOYSA-N 2-methyl-n-[2-[3-[[2-(prop-2-enoylamino)acetyl]amino]anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide Chemical compound C1=C(C(=O)NC=2C=NC(NC=3C=C(NC(=O)CNC(=O)C=C)C=CC=3)=NC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 SMOPKEHQPPXRSH-UHFFFAOYSA-N 0.000 claims description 15
SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 claims description 15
229940126656 GS-4224 Drugs 0.000 claims description 15
ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 15
DQPJVNQWPBLBAB-UHFFFAOYSA-N n-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=CC(CNC(C)C(C)(C)C)=CC=C1C(=O)NC(S1)=NC=C1SCC1=CC(C)=C(C)C(C(=O)N2CCN(CC2)C(C)=O)=C1 DQPJVNQWPBLBAB-UHFFFAOYSA-N 0.000 claims description 15
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 11
125000002947 alkylene group Chemical group 0.000 claims description 11
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 10
206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 10
125000004414 alkyl thio group Chemical group 0.000 claims description 10
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 10
125000001188 haloalkyl group Chemical group 0.000 claims description 10
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims description 9
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 9
206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 9
ZHXNIYGJAOPMSO-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)(C)C)C=C1 ZHXNIYGJAOPMSO-UHFFFAOYSA-N 0.000 claims description 9
201000007180 bile duct carcinoma Diseases 0.000 claims description 9
201000006587 bladder adenocarcinoma Diseases 0.000 claims description 9
201000005389 breast carcinoma in situ Diseases 0.000 claims description 9
208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 9
125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
201000009777 distal biliary tract carcinoma Diseases 0.000 claims description 9
201000007273 ductal carcinoma in situ Diseases 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
125000005549 heteroarylene group Chemical group 0.000 claims description 9
206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 9
201000010985 invasive ductal carcinoma Diseases 0.000 claims description 9
206010073096 invasive lobular breast carcinoma Diseases 0.000 claims description 9
201000011059 lobular neoplasia Diseases 0.000 claims description 9
201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 9
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 8
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
125000003710 aryl alkyl group Chemical group 0.000 claims description 8
125000004093 cyano group Chemical group *C#N 0.000 claims description 8
125000004438 haloalkoxy group Chemical group 0.000 claims description 8
125000004475 heteroaralkyl group Chemical group 0.000 claims description 8
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 8
CDOOFZZILLRUQH-GDLZYMKVSA-N n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)[C@H]1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-GDLZYMKVSA-N 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
125000004660 phenylalkylthio group Chemical group 0.000 claims description 8
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 8
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
206010023774 Large cell lung cancer Diseases 0.000 claims description 7
238000001990 intravenous administration Methods 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
239000007909 solid dosage form Substances 0.000 claims description 6
230000002611 ovarian Effects 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 2
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
238000011161 development Methods 0.000 abstract description 4
208000037765 diseases and disorders Diseases 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 48
210000004027 cell Anatomy 0.000 description 39
229940079593 drug Drugs 0.000 description 29
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 28
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 28
125000004429 atom Chemical group 0.000 description 26
201000011510 cancer Diseases 0.000 description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
206010024627 liposarcoma Diseases 0.000 description 21
201000008968 osteosarcoma Diseases 0.000 description 21
238000009472 formulation Methods 0.000 description 20
125000005842 heteroatom Chemical group 0.000 description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
238000002560 therapeutic procedure Methods 0.000 description 19
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 18
241000699666 Mus <mouse, genus> Species 0.000 description 16
201000010099 disease Diseases 0.000 description 16
125000004432 carbon atom Chemical group C* 0.000 description 15
230000002354 daily effect Effects 0.000 description 15
208000005243 Chondrosarcoma Diseases 0.000 description 14
201000008808 Fibrosarcoma Diseases 0.000 description 14
206010073137 Myxoid liposarcoma Diseases 0.000 description 14
230000024245 cell differentiation Effects 0.000 description 14
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
125000004122 cyclic group Chemical group 0.000 description 14
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 14
230000000694 effects Effects 0.000 description 14
230000004044 response Effects 0.000 description 14
235000018417 cysteine Nutrition 0.000 description 13
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
125000005843 halogen group Chemical group 0.000 description 13
210000004072 lung Anatomy 0.000 description 13
241000699660 Mus musculus Species 0.000 description 12
206010041067 Small cell lung cancer Diseases 0.000 description 12
208000000587 small cell lung carcinoma Diseases 0.000 description 12
238000001356 surgical procedure Methods 0.000 description 12
238000011830 transgenic mouse model Methods 0.000 description 12
230000002411 adverse Effects 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
208000029742 colonic neoplasm Diseases 0.000 description 11
239000008194 pharmaceutical composition Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
208000003174 Brain Neoplasms Diseases 0.000 description 10
230000036210 malignancy Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
206010008342 Cervix carcinoma Diseases 0.000 description 9
206010027476 Metastases Diseases 0.000 description 9
208000000453 Skin Neoplasms Diseases 0.000 description 9
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 9
210000000988 bone and bone Anatomy 0.000 description 9
201000010881 cervical cancer Diseases 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
201000001342 Fallopian tube cancer Diseases 0.000 description 8
208000013452 Fallopian tube neoplasm Diseases 0.000 description 8
206010019280 Heart failures Diseases 0.000 description 8
208000015634 Rectal Neoplasms Diseases 0.000 description 8
102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 8
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
238000013461 design Methods 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
239000013038 irreversible inhibitor Substances 0.000 description 8
201000001441 melanoma Diseases 0.000 description 8
201000000849 skin cancer Diseases 0.000 description 8
206010041823 squamous cell carcinoma Diseases 0.000 description 8
230000004083 survival effect Effects 0.000 description 8
108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 7
208000005748 Aggressive Fibromatosis Diseases 0.000 description 7
208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 7
206010061424 Anal cancer Diseases 0.000 description 7
201000003076 Angiosarcoma Diseases 0.000 description 7
208000007860 Anus Neoplasms Diseases 0.000 description 7
206010073360 Appendix cancer Diseases 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
206010007559 Cardiac failure congestive Diseases 0.000 description 7
201000009047 Chordoma Diseases 0.000 description 7
206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 7
206010065859 Congenital fibrosarcoma Diseases 0.000 description 7
206010073135 Dedifferentiated liposarcoma Diseases 0.000 description 7
206010059352 Desmoid tumour Diseases 0.000 description 7
208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 7
206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 7
206010061818 Disease progression Diseases 0.000 description 7
208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 7
201000005231 Epithelioid sarcoma Diseases 0.000 description 7
208000000461 Esophageal Neoplasms Diseases 0.000 description 7
208000006168 Ewing Sarcoma Diseases 0.000 description 7
208000016803 Extraskeletal Ewing sarcoma Diseases 0.000 description 7
201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 7
208000007569 Giant Cell Tumors Diseases 0.000 description 7
208000006050 Hemangiopericytoma Diseases 0.000 description 7
208000001258 Hemangiosarcoma Diseases 0.000 description 7
201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 7
206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 7
201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 7
208000007766 Kaposi sarcoma Diseases 0.000 description 7
208000008839 Kidney Neoplasms Diseases 0.000 description 7
208000032271 Malignant tumor of penis Diseases 0.000 description 7
208000000172 Medulloblastoma Diseases 0.000 description 7
201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 7
208000003445 Mouth Neoplasms Diseases 0.000 description 7
206010066948 Myxofibrosarcoma Diseases 0.000 description 7
208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 7
206010030155 Oesophageal carcinoma Diseases 0.000 description 7
208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 7
208000013612 Parathyroid disease Diseases 0.000 description 7
208000002471 Penile Neoplasms Diseases 0.000 description 7
206010034299 Penile cancer Diseases 0.000 description 7
208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 7
208000007913 Pituitary Neoplasms Diseases 0.000 description 7
206010038389 Renal cancer Diseases 0.000 description 7
206010073139 Round cell liposarcoma Diseases 0.000 description 7
208000005718 Stomach Neoplasms Diseases 0.000 description 7
208000024313 Testicular Neoplasms Diseases 0.000 description 7
206010057644 Testis cancer Diseases 0.000 description 7
206010043515 Throat cancer Diseases 0.000 description 7
208000024770 Thyroid neoplasm Diseases 0.000 description 7
208000002495 Uterine Neoplasms Diseases 0.000 description 7
206010047741 Vulval cancer Diseases 0.000 description 7
208000004354 Vulvar Neoplasms Diseases 0.000 description 7
201000008395 adenosquamous carcinoma Diseases 0.000 description 7
206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 7
208000008524 alveolar soft part sarcoma Diseases 0.000 description 7
208000010029 ameloblastoma Diseases 0.000 description 7
201000011165 anus cancer Diseases 0.000 description 7
208000021780 appendiceal neoplasm Diseases 0.000 description 7
201000008791 bone leiomyosarcoma Diseases 0.000 description 7
208000035269 cancer or benign tumor Diseases 0.000 description 7
201000010882 cellular myxoid liposarcoma Diseases 0.000 description 7
201000000292 clear cell sarcoma Diseases 0.000 description 7
229940109239 creatinine Drugs 0.000 description 7
230000005750 disease progression Effects 0.000 description 7
201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 7
201000004101 esophageal cancer Diseases 0.000 description 7
208000032099 esthesioneuroblastoma Diseases 0.000 description 7
230000007717 exclusion Effects 0.000 description 7
208000020812 extrarenal rhabdoid tumor Diseases 0.000 description 7
208000024519 eye neoplasm Diseases 0.000 description 7
230000003328 fibroblastic effect Effects 0.000 description 7
206010017758 gastric cancer Diseases 0.000 description 7
201000010982 kidney cancer Diseases 0.000 description 7
208000003849 large cell carcinoma Diseases 0.000 description 7
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 7
201000008834 liposarcoma of bone Diseases 0.000 description 7
201000007270 liver cancer Diseases 0.000 description 7
208000014018 liver neoplasm Diseases 0.000 description 7
206010061526 malignant mesenchymoma Diseases 0.000 description 7
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 7
230000000873 masking effect Effects 0.000 description 7
208000029974 neurofibrosarcoma Diseases 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
201000008106 ocular cancer Diseases 0.000 description 7
208000022560 parathyroid gland disease Diseases 0.000 description 7
201000003434 periosteal osteogenic sarcoma Diseases 0.000 description 7
208000010916 pituitary tumor Diseases 0.000 description 7
201000009463 pleomorphic rhabdomyosarcoma Diseases 0.000 description 7
208000029340 primitive neuroectodermal tumor Diseases 0.000 description 7
206010038038 rectal cancer Diseases 0.000 description 7
201000001275 rectum cancer Diseases 0.000 description 7
201000009410 rhabdomyosarcoma Diseases 0.000 description 7
201000008864 small cell osteogenic sarcoma Diseases 0.000 description 7
208000014653 solitary fibrous tumor Diseases 0.000 description 7
201000011549 stomach cancer Diseases 0.000 description 7
239000000126 substance Substances 0.000 description 7
206010042863 synovial sarcoma Diseases 0.000 description 7
201000011080 telangiectatic osteogenic sarcoma Diseases 0.000 description 7
201000003120 testicular cancer Diseases 0.000 description 7
201000002510 thyroid cancer Diseases 0.000 description 7
206010044412 transitional cell carcinoma Diseases 0.000 description 7
208000010576 undifferentiated carcinoma Diseases 0.000 description 7
210000002700 urine Anatomy 0.000 description 7
206010046766 uterine cancer Diseases 0.000 description 7
206010046885 vaginal cancer Diseases 0.000 description 7
208000013139 vaginal neoplasm Diseases 0.000 description 7
201000005102 vulva cancer Diseases 0.000 description 7
108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
201000010395 Pleomorphic liposarcoma Diseases 0.000 description 6
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 6
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 6
238000001574 biopsy Methods 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
206010061289 metastatic neoplasm Diseases 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
239000002245 particle Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
208000032843 Hemorrhage Diseases 0.000 description 5
241000725303 Human immunodeficiency virus Species 0.000 description 5
206010027457 Metastases to liver Diseases 0.000 description 5
108091000080 Phosphotransferase Proteins 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
206010003119 arrhythmia Diseases 0.000 description 5
208000034158 bleeding Diseases 0.000 description 5
230000000740 bleeding effect Effects 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
238000001839 endoscopy Methods 0.000 description 5
230000008595 infiltration Effects 0.000 description 5
238000001764 infiltration Methods 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
208000010125 myocardial infarction Diseases 0.000 description 5
239000008188 pellet Substances 0.000 description 5
102000020233 phosphotransferase Human genes 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
238000002271 resection Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000009121 systemic therapy Methods 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000001554 Hemoglobins Human genes 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
208000007814 Unstable Angina Diseases 0.000 description 4
239000000654 additive Substances 0.000 description 4
150000003973 alkyl amines Chemical class 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
238000002591 computed tomography Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
239000001301 oxygen Chemical group 0.000 description 4
239000006187 pill Substances 0.000 description 4
230000002980 postoperative effect Effects 0.000 description 4
208000037821 progressive disease Diseases 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000011593 sulfur Chemical group 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
208000009458 Carcinoma in Situ Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
206010059282 Metastases to central nervous system Diseases 0.000 description 3
102100024028 Progonadoliberin-1 Human genes 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 3
238000008050 Total Bilirubin Reagent Methods 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
150000001336 alkenes Chemical class 0.000 description 3
150000001345 alkine derivatives Chemical group 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
229940120638 avastin Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
210000003679 cervix uteri Anatomy 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
230000002254 contraceptive effect Effects 0.000 description 3
125000002993 cycloalkylene group Chemical group 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940000406 drug candidate Drugs 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000003709 fluoroalkyl group Chemical group 0.000 description 3
230000036541 health Effects 0.000 description 3
208000019622 heart disease Diseases 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
201000004933 in situ carcinoma Diseases 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000002595 magnetic resonance imaging Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
125000002950 monocyclic group Chemical group 0.000 description 3
230000035772 mutation Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
208000020016 psychiatric disease Diseases 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
208000020446 Cardiac disease Diseases 0.000 description 2
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
241000252212 Danio rerio Species 0.000 description 2
206010011878 Deafness Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
208000009139 Gilbert Disease Diseases 0.000 description 2
208000022412 Gilbert syndrome Diseases 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
101001010823 Homo sapiens Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
101000669434 Mus musculus Transducin-like enhancer protein 1 Proteins 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
229910007161 Si(CH3)3 Inorganic materials 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000009098 adjuvant therapy Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000004450 alkenylene group Chemical group 0.000 description 2
239000003098 androgen Substances 0.000 description 2
238000011225 antiretroviral therapy Methods 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
125000002393 azetidinyl group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
239000013068 control sample Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
238000012325 curative resection Methods 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
229960005277 gemcitabine Drugs 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000010370 hearing loss Effects 0.000 description 2
231100000888 hearing loss Toxicity 0.000 description 2
208000016354 hearing loss disease Diseases 0.000 description 2
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
208000031169 hemorrhagic disease Diseases 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
230000002962 histologic effect Effects 0.000 description 2
208000019016 inability to swallow Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000003908 liver function Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
201000005296 lung carcinoma Diseases 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000007726 management method Methods 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
230000009251 neurologic dysfunction Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
230000000683 nonmetastatic effect Effects 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
125000003367 polycyclic group Chemical group 0.000 description 2
238000010837 poor prognosis Methods 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000001514 prostate carcinoma Diseases 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000004904 shortening Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
208000020352 skin basal cell carcinoma Diseases 0.000 description 2
201000010106 skin squamous cell carcinoma Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
125000000335 thiazolyl group Chemical group 0.000 description 2
150000007970 thio esters Chemical group 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
230000008736 traumatic injury Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
229960005080 warfarin Drugs 0.000 description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical compound C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
206010060921 Abdominal abscess Diseases 0.000 description 1
206010001367 Adrenal insufficiency Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091007743 BRCA1/2 Proteins 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
208000002251 Dissecting Aneurysm Diseases 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
206010018001 Gastrointestinal perforation Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
101000984551 Homo sapiens Tyrosine-protein kinase Blk Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020802 Hypertensive crisis Diseases 0.000 description 1
208000019025 Hypokalemia Diseases 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000007666 Klatskin Tumor Diseases 0.000 description 1
101150036626 LSR gene Proteins 0.000 description 1
108040008097 MAP kinase activity proteins Proteins 0.000 description 1
102000019149 MAP kinase activity proteins Human genes 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
206010025652 Malignant melanoma in situ Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000007650 Meningeal Carcinomatosis Diseases 0.000 description 1
206010027450 Metastases to abdominal cavity Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000008457 Neurologic Manifestations Diseases 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
208000005228 Pericardial Effusion Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000018452 Torsade de pointes Diseases 0.000 description 1
208000002363 Torsades de Pointes Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
102100027053 Tyrosine-protein kinase Blk Human genes 0.000 description 1
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
208000011930 active peptic ulcer disease Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000005084 alkoxyalkylaminoalkyl group Chemical group 0.000 description 1
125000005055 alkyl alkoxy group Chemical group 0.000 description 1
125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
125000005189 alkyl hydroxy group Chemical group 0.000 description 1
125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
125000004419 alkynylene group Chemical group 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000009167 androgen deprivation therapy Methods 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
229940127088 antihypertensive drug Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
206010002895 aortic dissection Diseases 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000005362 aryl sulfone group Chemical group 0.000 description 1
125000005361 aryl sulfoxide group Chemical group 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000000732 arylene group Chemical group 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037180 bone health Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
208000011825 carcinoma of the ampulla of vater Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000002060 circadian Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000012321 colectomy Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
201000004365 colon carcinoma in situ Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000000991 decompressive effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
125000005883 dithianyl group Chemical group 0.000 description 1
125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000013265 extended release Methods 0.000 description 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000003862 health status Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
125000006588 heterocycloalkylene group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
102000053810 human ERBB4 Human genes 0.000 description 1
WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
229940091173 hydantoin Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
201000009939 hypertensive encephalopathy Diseases 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000002576 ketones Chemical group 0.000 description 1
238000002372 labelling Methods 0.000 description 1
150000003951 lactams Chemical group 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000004731 long QT syndrome Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000001095 motoneuron effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
229960000572 olaparib Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003551 oxepanyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
230000009996 pancreatic endocrine effect Effects 0.000 description 1
208000012111 paraneoplastic syndrome Diseases 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000011129 pharmaceutical packaging material Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
208000024896 potassium deficiency disease Diseases 0.000 description 1
238000009101 premedication Methods 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000011164 rectum carcinoma in situ Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
201000006000 skin carcinoma in situ Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
231100000019 skin ulcer Toxicity 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229960002317 succinimide Drugs 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000001583 thiepanyl group Chemical group 0.000 description 1
125000002053 thietanyl group Chemical group 0.000 description 1
125000005309 thioalkoxy group Chemical group 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
210000000779 thoracic wall Anatomy 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
208000029584 urinary system neoplasm Diseases 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
210000000504 visceral peritoneum Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1